Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q3 2023 Earnings Presentation

56 slides from Walgreens Boots Alliance's earnings presentation, Jun 27, 2023

  1. Slide 1: Reimagining Local Healthcare and Wellbeing for All

    Reimagining Local Healthcare and Wellbeing for All Third Quarter Fiscal 2023 Results June 27, 2023 © 2023 Walgreens Boots Alliance, Inc. All rights reserved.

  2. Slide 2: Safe Harbor and Non-GAAP

    Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat

  3. Slide 3: Transforming core retail pharmacy business while managing through consumer headwinds

    Transforming core retail pharmacy business while managing through consumer headwinds Scaling and driving profitability of our Four strategic healthcare assets across the care continuum priorities underpin our transformation Focusing and simplifying our portfolio, and optimizing capital allocation In

  4. Slide 4: Good progress across our four strategic priorities year-to-date

    Good progress across our four strategic priorities year-to-date • Advancing tech-enabled pharmacy operating model through digital, telepharmacy capabilities • Microfulfillment centers now supporting over 40% of store footprint Transform and align the core • Flat U.S. retail comp sales YTD lapping +8

  5. Slide 5: Returned to growth with 3Q adj. EPS +3.6%

    Returned to growth with 3Q adj. EPS +3.6% • Sales +8.9% on a constant currency basis, exceeding expectations, driven by solid core business and rapidly scaling healthcare growth engine • Adj. EPS growth of +3.6% on a constant currency basis was held back by: − Lower COVID-related demand − Softening

  6. Slide 6: Updating FY23 guidance and providing preliminary FY24 commentary

    Updating FY23 guidance and providing preliminary FY24 commentary • Updating FY23 adj. EPS guidance to $4.00-$4.05 to reflect consumer and category trends, lower COVID-19 related contribution, and a more cautious macroeconomic forward view; expecting FY23 core adj. EPS flat to +1% ex. COVID-19 and Fx

  7. Slide 7: Taking immediate actions to drive shareholder value

    Taking immediate actions to drive shareholder value • Raising Transformational Cost Management Program goal, with $800 million of cost savings expected in FY24 • Implemented capital and project spend reductions; working capital optimization program launched, benefitting FY24 • Advancing portfolio si

  8. Slide 8: We are integrating our care delivery assets to drive growth

    We are integrating our care delivery assets to drive growth CORE RETAIL PHARMACY SERVES AS CORNERSTONE OF CARE DELIVERY Aggregate addressable value per Trusted brand with close connection customer increases significantly Faster Tech- to consumers Core enabled Growth experience Healthcare and Pharmac

  9. Slide 9: Enterprise-wide approach to healthcare delivery drives sales growth

    Enterprise-wide approach to healthcare delivery drives sales growth Best-in-class value-based Outcomes-driven post- Next generation of Enabling population health primary care acute care specialty pharmacy • Team-based approach to • STARS/HEDIS gap closures • Conversion of Walgreens • Expanding exist

  10. Slide 10: 3Q 2023 financial highlights

    3Q 2023 financial highlights • Constant currency sales growth +8.9% − U.S. comparable sales +7.0%, led by Pharmacy +9.8%, with Retail ex. tobacco +0.2% − International constant currency sales +6.9%, led by Boots UK comparable retail sales +13.4% − U.S. Healthcare pro forma segment sales growth of +2

  11. Slide 11: WBA 3Q23 Financial Highlights

    Reported Fx Constant Fx 3Q23 $ in millions (except EPS) B/(W) vs. 3Q22 B/(W) vs. 3Q22 Sales $35,415 + 8.6% + 8.9% Operating Income GAAP ($477) ($157) Adjusted $959 + 0.4% + 0.6% WBA 3Q23 Financial Net Earnings GAAP $118 ($171) Highlights Adjusted $860 + 3.1% + 3.4% EPS GAAP $0.14 ($0.20) Adjusted $1

  12. Slide 12: WBA Year-to-Date Financial Highlights

    Reported Fx Constant Fx YTD23 $ in millions (except EPS) B/(W) vs. YTD22 B/(W) vs. YTD22 Sales $103,659 + 3.4% + 4.8% Operating Income GAAP ($6,431) ($8,640) Adjusted $3,188 (27.4)% (26.6)% WBA Year-to- Date Financial Net Earnings GAAP ($2,900) ($7,652) Highlights Adjusted $2,864 (21.9)% (20.9)% EPS

  13. Slide 13: U.S. Retail Pharmacy Financials

    B/(W) vs. 3Q23 B/(W) vs. 3Q22 YTD23 $ in millions YTD22 Sales $27,866 + 4.4% $82,648 + 0.3% Adj. gross profit $5,383 (3.2)% $17,143 (6.9)% U.S. Retail Adj. SG&A % of sales 16.3% 1.6%p 17.4% 0.4%p Pharmacy Adj. operating income $962 (0.4)% $3,134 (26.1)% Financials Adj. operating margin1 3.0% + 0.1%p

  14. Slide 14: U.S. Pharmacy

    3Q23 3Q23 YTD23 YTD23 3Q23 vs. 3Q22 | YTD23 vs. YTD22 Total Comparable Total Comparable Pharmacy sales + 6.3% + 9.8% + 0.7% + 6.5% Prescriptions + 0.3% + 1.6% (0.4)% (0.6)% Prescriptions ex. + 1.5% + 2.8% + 1.8% + 2.8% Immunizations U.S. Pharmacy • Comp sales +9.8% with growth primarily due to brand

  15. Slide 15: U.S. Retail

    3Q23 YTD23 3Q23 vs. 3Q22 | YTD23 vs. YTD22 Total retail sales (1.0)% (0.7)% Comparable retail sales (0.2)% + 0.0% • Comp ex. tobacco +0.2% including 90 bps impact from holiday seasonal weakness and 80 U.S. Retail bps drag from lower sales of OTC test kits − Comp led by strength in grocery & househol

  16. Slide 16: International Financials

    Constant Fx Constant Fx 3Q23 YTD23 $ in millions B/(W) vs. 3Q22 B/(W) vs. YTD22 Sales $5,573 + 6.9% $16,414 + 6.8% Adj. gross profit $1,173 + 10.3% $3,421 + 6.5% Adj. SG&A % of sales 17.3% (0.2)%p 16.7% + 0.7%p International Adj. operating income $208 + 20.9% $676 + 26.9% Financials Adj. operating m

  17. Slide 17: Boots UK Financials

    3Q23 YTD23 3Q23 vs. 3Q22 | YTD23 vs. YTD22 (constant Fx) Pharmacy comp. sales + 5.7% + 2.1% Retail comp. sales + 13.4% + 12.7% Boots UK • Pharmacy comp sales +5.7%, the best performance in 6 quarters Financials • Strong retail comp sales +13.4% in 3Q − Store footfall improved +7% vs. prior year − Co

  18. Slide 18: U.S. Healthcare Financials

    3Q23 B/(W) vs. 3Q22 YTD23 B/(W) vs. YTD22 $ in millions Sales $1,975 + $1,379 $4,597 + $3,424 Adj. gross profit $114 + $135 $267 + $253 Adj. SG&A ($286) ($179) ($750) ($517) U.S. Healthcare Adj. operating loss ($172) ($44) ($483) ($265) Financials Adj. EBITDA ($113) ($7) ($346) ($168) • U.S. Healthc

  19. Slide 19: U.S. Healthcare Key Metrics

    Current Status1 Organic Contracted Lives2 2.9M Organic Partners (Payor/Provider)2 4 VillageMD/Summit Health Value-Based Lives3 850K Sites of Care: Health Corners 116 VillageMD Co-Located Clinics 217 U.S. Healthcare Total VillageMD/Summit/CityMD Locations 870 Key Metrics Pro Forma YOY $ millions 3Q23

  20. Slide 20: Cash Flow

    B/(W) YTD23 $ in millions vs. YTD22 Operating cash flow $1,219 ($2,595) Cash capital expenditures ($1,633) ($392) Acquisition-related payments $530 $530 Free cash flow $116 ($2,457) Cash Flow • YTD cash generation of $1.2 billion in operating cash flow and $116 million of free cash flow • Year-over-

  21. Slide 21: WBA FY23 Outlook

    Expecting core adj. EPS flat to +1% FY23 guidance Adj. EPS growth October 2022 June 2023 Adjusted EPS $4.45-$4.65 $4.00-$4.05 % growth YOY (8)-(12)% (20)-(21)% WBA FY23 Fx impact ~(2)% ~(1)% Outlook % growth YOY CFx (6)-(10)% (19)-(20)% COVID-19 headwind (15)-(17)% ~(20)% Core business growth + 8-10

  22. Slide 22: FY23 segment assumptions

    FY23 segment assumptions FY23 (Oct-22) FY23 (Jun-23) Comments Sales $130.5 - $134.0B $137.3 - $139.3B • Sales raised with Summit Health deal, U.S. Retail Pharmacy upside, Fx WBA • AOI reflects consumer & COVID-19 headwinds, AOI $4.7 - $4.9B $3.9 - $4.1B U.S. Healthcare below expectations • YTD sales

  23. Slide 23: FY23 corporate assumptions

    FY23 corporate assumptions $ millions FY23 (Oct-22) FY23 (Jun-23) Comments • Better than expected performance through 3Q to Adj. Tax Rate ~16% ~12% reverse with 4Q adjusted tax rate of ~23% • Higher debt levels related to Summit Health Interest Expense $(500) - $(490) $(600) - $(580) transaction and

  24. Slide 24: WBA FY24 Preliminary Commentary

    Long-term tailwinds outweigh near-term headwinds Tailwinds Headwinds • U.S. Healthcare scaling and synergies, with • Consumer sentiment and spending significant step-up in profitability • Ongoing reimbursement pressure WBA FY24 • • Targeted actions to improve profitability Maturing VillageMD clinic

  25. Slide 25: Expecting LSD-MSD AOI growth; AOI growth outpaces adj. EPS

    Expecting LSD-MSD AOI growth; AOI growth outpaces adj. EPS due to higher tax rate/non-controlling interest • Expecting significant AOI growth from first full year of Summit Health, VillageMD clinic maturation, and Shields/CareCentrix U.S. Healthcare • Taking immediate actions to optimize path to pro

  26. Slide 26: U.S. Pharmacy Profit Growth Drivers

    Expecting U.S. pharmacy gross profit growth ex. COVID-19 • Differentiated tech-enabled operating model underpins growth; becoming the pharmacy practice setting of choice • Expecting solid comp script growth ex. immunizations from improved U.S. Pharmacy operating hours, increased access, and growth i

  27. Slide 27: U.S. Retail Profit Growth Drivers

    Projecting retail gross profit growth led by LSD comp growth and continued margin improvement • Category performance improvement program enables assortment decisions delivering at least $200 million run-rate savings by FY24 U.S. Retail • Accelerating margin-accretive owned brands Profit Growth • Dri

  28. Slide 28: U.S. Healthcare Right to Win

    Quickly scaling our U.S. Healthcare business with sharper focus on profitability • Unique capabilities: Leveraging our trusted brand and high-quality assets to create significant synergies with Walgreens and be the independent partner of choice • Scaling business: Exiting FY23 with run-rate sales ~$

  29. Slide 29: Summit Health Profit Drivers

    Summit Health expected to drive meaningful U.S. Healthcare AOI growth • First full year of profit contribution in FY24 • Rebound in top-line growth at CityMD, driven by targeted marketing Summit • Improving profit from optimizing CityMD clinic operations and integrating Health Profit prior Summit ac

  30. Slide 30: VillageMD Profit Drivers

    VillageMD leveraging existing scale to pivot to profitable growth • Optimizing for regional density in existing markets • Exploring new asset-light and virtual models to improve access and return on investment VillageMD Profit Drivers • Focusing marketing efforts to drive overall patient panel growt

  31. Slide 31: Scaling VillageMD's Model

    Demonstrated ability to lower Medicare Advantage medical loss ratio (MLR) over time 88.0% 86.8% 76.4% 78.7% 74.0% 78.3% 79.2% 71.9% 71.1% Scaling VillageMD’s Model Arizona Georgia Houston 2021 2022 2023E • MLR performance has been strong across strategic markets Note: 2023E performance based on same

  32. Slide 32: Aligning enterprise B2B sales and contracting teams under experienced healthcare leadership

    Aligning enterprise B2B sales and contracting teams under recently- appointed, experienced healthcare leadership Driving results: • Horizon Blue Cross Blue Shield signed as Health Corners Payors fourth payor partner for Walgreens Health B2B Sales & Health • Shields and CareCentrix signed new deals C

  33. Slide 33: Capital Allocation Priorities

    Focus is on core investments, debt paydown, and dividend •1 Investment in the Core •2 Portfolio Simplification Business and Strategic M&A Capital • Disciplined, returns-based investment • Portfolio simplification to unlock value Allocation with reprioritized project spend • Value-accretive M&A (bolt

  34. Slide 34: Raising Transformational Cost Management Program target to $4.1 billion

    Raising Transformational Cost Management Program target to $4.1 billion with $800 million of savings in FY24 Incremental In-Year Savings Cumulative Savings • Increased goal driven by execution to date and Savings in $B expansion of program FY19 + $0.3 $0.3 • Sixth target increase since program incep

  35. Slide 35: Increased cost management savings target supported by new initiatives

    Increased Transformational Cost Management Program savings target supported by new initiatives Organization restructuring Transforming headquarters to better align to strategic priorities Pharmacy of the future operating model Optimizing labor model elevating pharmacist and patient engagement, AI/te

  36. Slide 36: Accelerating portfolio simplification

    Accelerating portfolio simplification Reached agreement for the sale of the Farmacias Ahumada chain in Chile, with transaction expected to be completed by the end of calendar 2023 Completed exit from Option Care Health with sale of remaining 10.8 million shares for proceeds of approximately $330 mil

  37. Slide 37: Building momentum and accelerating our healthcare transformation

    Building momentum and accelerating our healthcare transformation • Returned to adj. EPS growth in 3Q with strong sales growth • Taking immediate actions to drive sustainable core growth and deliver shareholder value • Pivoting our healthcare focus to accelerating profitability • Fueling our transfor

  38. Slide 38: Q&A

    Q&A © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 38

  39. Slide 39: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures. • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  40. Slide 40: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  41. Slide 41: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except net debt ratio and lease adjusted net debt ratio) The Company defines net debt ratio as net debt divided by adjusted earnings before interest, tax,

  42. Slide 42: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET LOSS TO ADJUSTED OPERATING INCOME, ADJUSTED EBITDA and ADJUSTED EBITDAR As Reported Twelve months ended May 31, 2023 Net loss (GAAP) $ (3,821) Post-tax

  43. Slide 43: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa

  44. Slide 44: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET EARNINGS (LOSS) TO ADJUSTED NET EARNINGS AND DILUTED NET EARNINGS (LOSS) PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE

  45. Slide 45: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET EARNINGS (LOSS) TO ADJUSTED NET EARNINGS AND DILUTED NET EARNINGS (LOSS) PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE

  46. Slide 46: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa

  47. Slide 47: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,866 $ 5,5

  48. Slide 48: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended May 31, 2022 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 26,695 $ 5,3

  49. Slide 49: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 82,648 $ 16,4

  50. Slide 50: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Nine months ended May 31, 2022 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 82,394 $ 16,6

  51. Slide 51: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating income (loss) for U.S. Retail Pharmacy includes equity earnings in AmerisourceBergen. As a result of the two-month reporting lag, operating income (loss) for

  52. Slide 52: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) OPERATING LOSS TO ADJUSTED EBITDA FOR THE U.S. HEALTHCARE SEGMENT Three months ended May 31, Nine months ended May 31, 2023 2022 2023 2022 Operating loss (

  53. Slide 53: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN AMERISOURCEBERGEN Three months ended May 31, Nine months ended May 31, 2023 2022 2023 2022 Equity earnings in AmerisourceBergen (GAAP) $

  54. Slide 54: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended May 31, 2023 Three months ended May 31, 2022 (Loss) earnings Income tax (Loss) earnings Income tax before in

  55. Slide 55: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended May 31, Nine months ended May 31, 2023 2022 2023 2022 Net cash (used for) provided by operating activities (GAAP) $ (20)

  56. Slide 56: Supplemental Financial Information

    Supplemental Financial Information Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Supplemental sale-leaseback financial information Three months ended Nine months ended May 31, 2023 Change vs. 3Q22 May 31, 2023 Change vs. FY22 U.S. Retail Pharmacy

Walgreens Boots Alliance — Q3 2023 Earnings Presentation on 6ix